Total Payments
$103,512
2024 Payments
$39,536
Companies
31
Transactions
224
Medicare Patients
1,144
Medicare Billing
$137,279
Payment Breakdown by Category
Other$73,186 (70.7%)
Travel$12,737 (12.3%)
Consulting$11,436 (11.0%)
Food & Beverage$6,025 (5.8%)
Education$127.45 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $73,186 | 44 | 70.7% |
| Travel and Lodging | $12,737 | 52 | 12.3% |
| Consulting Fee | $11,436 | 5 | 11.0% |
| Food and Beverage | $6,025 | 120 | 5.8% |
| Education | $127.45 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ARGENX US, INC. | $50,890 | 73 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $34,732 | 64 | $0 (2024) |
| Shire North American Group Inc | $14,190 | 22 | $0 (2019) |
| PFIZER INC. | $781.70 | 2 | $0 (2023) |
| GENZYME CORPORATION | $409.84 | 4 | $0 (2024) |
| Amgen Inc. | $360.47 | 5 | $0 (2020) |
| Biogen, Inc. | $237.05 | 9 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $216.00 | 3 | $0 (2021) |
| Alexion Pharmaceuticals, Inc. | $180.72 | 3 | $0 (2023) |
| Allergan, Inc. | $162.02 | 6 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,536 | 60 | ARGENX US, INC. ($22,861) |
| 2023 | $20,934 | 40 | ARGENX US, INC. ($16,328) |
| 2022 | $21,535 | 39 | ARGENX US, INC. ($11,701) |
| 2021 | $3,821 | 18 | Takeda Pharmaceuticals U.S.A., Inc. ($3,558) |
| 2020 | $2,251 | 10 | Takeda Pharmaceuticals U.S.A., Inc. ($2,041) |
| 2019 | $10,284 | 36 | Shire North American Group Inc ($9,651) |
| 2018 | $4,735 | 14 | Shire North American Group Inc ($4,539) |
| 2017 | $416.73 | 7 | Allergan Inc. ($104.78) |
All Payment Transactions
224 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/29/2024 | ARGENX US, INC. | VYVGART (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: Immunology | ||||||
| 11/29/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $89.92 | General |
| Category: Immunology | ||||||
| 11/29/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $3.99 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Amicus Therapeutics, Inc. | Pombiliti (Drug), Opfolda | Food and Beverage | In-kind items and services | $119.59 | General |
| Category: Pompe Disease | ||||||
| 11/07/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Neurology | ||||||
| 10/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $991.91 | General |
| 10/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $311.52 | General |
| 10/03/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $102.59 | General |
| Category: Neurology | ||||||
| 08/29/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: IMMUNOLOGY | ||||||
| 08/28/2024 | ARGENX US, INC. | VYVGART (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Immunology | ||||||
| 08/28/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $165.68 | General |
| Category: Immunology | ||||||
| 08/28/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $3.99 | General |
| Category: Immunology | ||||||
| 08/15/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $112.72 | General |
| 07/24/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $89.00 | General |
| Category: Immunology | ||||||
| 07/22/2024 | ARGENX US, INC. | VYVGART (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Immunology | ||||||
| 07/19/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $98.24 | General |
| Category: Immunology | ||||||
| 06/27/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $102.27 | General |
| Category: Immunology | ||||||
| 06/11/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $664.30 | General |
| Category: Immunology | ||||||
| 06/11/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| Category: Immunology | ||||||
| 06/06/2024 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: Immunology | ||||||
| 05/22/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,695.50 | General |
| Category: IMMUNOLOGY | ||||||
| 05/21/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $341.62 | General |
| Category: Immunology | ||||||
| 05/21/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| Category: Immunology | ||||||
| 05/20/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Travel and Lodging | In-kind items and services | $38.86 | General |
| Category: IMMUNOLOGY | ||||||
| 05/20/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Travel and Lodging | In-kind items and services | $25.46 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 257 | 297 | $115,441 | $31,286 |
| 2022 | 8 | 279 | 343 | $129,717 | $35,594 |
| 2021 | 9 | 285 | 328 | $118,499 | $32,980 |
| 2020 | 11 | 323 | 379 | $146,607 | $37,420 |
Total Patients
1,144
Total Services
1,347
Medicare Billing
$137,279
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 64 | 94 | $30,926 | $8,645 | 28.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 54 | 60 | $26,580 | $7,682 | 28.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 42 | 42 | $26,418 | $6,903 | 26.1% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 28 | 28 | $13,076 | $3,061 | 23.4% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 34 | 36 | $10,224 | $2,921 | 28.6% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 23 | 25 | $4,600 | $1,300 | 28.3% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 12 | 12 | $3,617 | $773.97 | 21.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 72 | 100 | $32,900 | $9,476 | 28.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 41 | 41 | $25,789 | $6,718 | 26.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 40 | 50 | $22,150 | $6,603 | 29.8% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 48 | 66 | $18,744 | $5,519 | 29.4% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 18 | 18 | $11,070 | $2,576 | 23.3% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2022 | 20 | 20 | $9,340 | $2,227 | 23.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 19 | 26 | $5,676 | $1,269 | 22.4% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2022 | 21 | 22 | $4,048 | $1,206 | 29.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 51 | 56 | $24,808 | $7,600 | 30.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 60 | 83 | $27,307 | $7,324 | 26.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 37 | 37 | $23,273 | $6,151 | 26.4% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 50 | 61 | $17,324 | $5,235 | 30.2% |
| 95909 | Nerve transmission studies, 5-6 studies | Office | 2021 | 19 | 19 | $8,873 | $2,225 | 25.1% |
| 95910 | Nerve transmission studies, 7-8 studies | Office | 2021 | 12 | 12 | $7,380 | $1,906 | 25.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 22 | $4,792 | $1,128 | 23.5% |
| 95885 | Needle measurement and recording of electrical activity of muscles of arm or leg limited study | Office | 2021 | 13 | 13 | $2,392 | $743.08 | 31.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 24 | 25 | $2,350 | $669.00 | 28.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 73 | 98 | $32,242 | $7,234 | 22.4% |
About Dr. Krishna Pokala, MD
Dr. Krishna Pokala, MD is a Neurology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/26/2011. The National Provider Identifier (NPI) number assigned to this provider is 1578856399.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Krishna Pokala, MD has received a total of $103,512 in payments from pharmaceutical and medical device companies, with $39,536 received in 2024. These payments were reported across 224 transactions from 31 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($73,186).
As a Medicare-enrolled provider, Pokala has provided services to 1,144 Medicare beneficiaries, totaling 1,347 services with total Medicare billing of $137,279. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Clinical Neurophysiology
- Location Austin, TX
- Active Since 05/26/2011
- Last Updated 03/15/2017
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1578856399
Products in Payments
- VYVGART (Drug) $47,824
- GAMMAGARD LIQUID (Biological) $18,502
- HYQVIA (Biological) $17,950
- GAMMAGARD (Biological) $4,833
- VYVGART HYTRULO (Drug) $2,903
- Aimovig (Biological) $261.62
- NURTEC ODT (Drug) $249.02
- SPINRAZA (Biological) $194.98
- ULTOMIRIS (Biological) $162.58
- Hizentra (Biological) $152.59
- BOTOX (Biological) $139.43
- FIRDAPSE (Drug) $129.47
- FABRAZYME (Biological) $125.00
- QULIPTA (Drug) $124.69
- TEGSEDI (Drug) $121.84
- Pombiliti (Drug) $119.59
- HYPERLIPIDEMIA - DISEASE (Drug) $100.00
- NUEDEXTA (Drug) $95.78
- ZEPATIER (Drug) $88.89
- AIMOVIG (Biological) $70.47
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Austin
Dr. Elliot Frohman, Md Phd, MD PHD
Neurology — Payments: $633,909
Neurology $633,909
Dr. David Morledge, M.d, M.D
Neurology — Payments: $180,453
Neurology $180,453
Dr. Sami Aboumatar, M.d, M.D
Neurology — Payments: $159,184
Neurology $159,184
Dr. Subhashie Wijemanne, M.d, M.D
Neurology — Payments: $140,816
Neurology $140,816
Dr. Rajat Gupta, M.d, M.D
Neurology — Payments: $91,931
Neurology $91,931
Dr. Robert Izor, Md, MD
Neurology — Payments: $70,941
Neurology $70,941